Status:
ACTIVE_NOT_RECRUITING
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
Lead Sponsor:
University Hospital, Geneva
Conditions:
Major Depressive Disorder (MDD)
Anxiety Disorders
Eligibility:
All Genders
18+ years
Brief Summary
This retrospective observational study examines the effects of psychedelic-assisted psychotherapy (PAP) with lysergic acid diethylamide (LSD) or psilocybin in patients with treatment-resistant depress...
Detailed Description
The overall project is a retrospective observational study evaluating the effects of psychedelic-assisted psychotherapy (PAP) with LSD or psilocybin in treatment-resistant depressive, anxiety, and add...
Eligibility Criteria
Inclusion
- Patients treated in the compassionate PAP program at Geneva University Hospitals between June 2020 and April 2025.
- Diagnosis of depressive, anxiety, or addictive disorder resistant to standard treatments.
- General consent for use of routinely collected clinical data.
- Federal Office of Public Health authorization for PAP.
Exclusion
- psychotic disorder
- bipolar disorder
- high suicidal risk
- severe cardiovascular disease
- severe liver disease
- neurological disease of the central nervous system
- pregnancy
- breastfeeding
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
376 Patients enrolled
Trial Details
Trial ID
NCT07164287
Start Date
June 1 2020
End Date
September 30 2025
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Geneva University Hospital
Geneva, Switzerland